Singapore, April 17 -- BioCell Innovations, a Singapore-based biotechnology startup pioneering next-generation CAR-T therapies, has been awarded a G-Rex Grant ($125,000) from ScaleReady to integrate its proprietary CAR manufacturing process with the highly efficient G-Rex platform.

BioCell Innovations has introduced a proprietary CAR-T manufacturing process that dramatically reduces cytokine-associated toxicities, particularly cytokine release syndrome (CRS), without compromising therapeutic potency. This next-generation platform delivers a cost-effective, scalable, and clinically adaptable solution, prioritising both patient safety and treatment efficacy.

"With the support of this grant, we aim to seamlessly integrate our manufacturing...